(Q38235456)

31 August 2017

title

Therapeutic vaccines for leishmaniasis (English)

1 reference

31 August 2017

1 reference

Ali Khamesipour

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

31 July 2014

1 reference

Expert Opinion on Biological Therapy

31 August 2017

published in

1 reference

31 August 2017

volume

14

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

1641-1649

1 reference

Leishmaniasis worldwide and global estimates of its incidence

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Clinical manifestations and classification of Old World cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunoactivation and immunopathogeny during active visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Vaccine candidates for leishmaniasis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Leishmaniasis chemotherapy--challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Systematic review of New World cutaneous leishmaniasis: several points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

The immunology of susceptibility and resistance to Leishmania major in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

CD8+ T Cells as a Source of IFN-γ Production in Human Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Differential in vitro CD4+/CD8+ T-cell response to live vs. killed Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

The development and clinical evaluation of second-generation leishmaniasis vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Leishmaniasis: vaccine candidates and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Case study for a vaccine against leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Emil Behring's medical culture: from disinfection to serotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunotherapy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Hark back: passive immunotherapy for influenza and other serious infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunotherapy for drug-refractory mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Leishmania-host interactions: what has imaging taught us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Natural killer cells in experimental and human leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Visceral leishmaniasis: immunology and prospects for a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Immunological perspectives of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Development of Vaccines against Visceral Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

Cytokine Gene Expression in Healing and Non-Healing Cases of Cutaneous Leishmaniasis in Response to In vitro Stimulation with Recombinant gp63 Using Semi-Quantitative RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.945415

10.1517/14712598.2014.945415

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference